Scientist II - Sr. Scientist, CRISPR Specificity & Genomic Safety

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures, and have raised over $150M to date. Profluent is seeking a creative and enthusiastic Scientist II - Sr. Scientist to build and apply experimental workflows that characterize the specificity, safety, and developability of our personalized CRISPR base editing platform. This role will initially focus on establishing and scaling base-editor specificity workflows , including biochemical and cell-based approaches such as CHANGE-seq-BE and related methods for identifying DNA and RNA off-target activity. In the longer term, the candidate will spearhead off-target assessments for novel gene editing platforms such as engineered recombinases. The candidate will work closely with protein engineering, cell biology, bioinformatics, automation, and program teams to generate decision-quality datasets that guide editor design, candidate selection, and therapeutic program development. This person will be responsible for benchmarking assays, interpreting NGS-based specificity data, identifying limitations and opportunities across methods, and building robust workflows that can be deployed across editing modalities and disease-relevant contexts. This is an excellent opportunity to shape how AI-designed genome editing systems are evaluated and advanced, and to work cross-functionally with a diverse team of experts across machine learning, protein engineering, cell biology, genomics, and gene editing. Responsibilities Build and lead Profluent’s strategy for base editor specificity assessment, with an emphasis on base-editor-relevant off-target discovery and validation workflows such as CHANGE-Seq-BE and related biochemical, cell-based, and targeted sequencing approaches Develop, optimize, benchmark, and apply orthogonal methods to evaluate editing specificity, including workflows for base editors, nucleases, and broader genomic integrity assessment across relevant experimental systems Design and execute studies to identify, prioritize, and validate potential off-target editing events, integrating assay development, NGS library preparation, sequencing QC, and data interpretation in partnership with computational biology and program teams Generate high-quality, decision-enabling datasets that inform editor engineering, guide/editor selection, delivery conditions, candidate nomination, and program development strategy Collaborate cross-functionally with protein engineering, cell biology, gene editing, bioinformatics, automation, and program teams to integrate specificity workflows into Profluent’s broader R&D infrastructure Establish robust experimental processes, documentation, and analysis frameworks to support reproducibility, scalability, assay qualification, and potential regulatory-facing genomic safety packages Present results and clearly communicate experimental strategy, timelines, risks, milestones, and program implications to diverse scientific and company stakeholders Provide mentorship and guidance to junior team members and peers, helping align goals, troubleshoot experiments, and maintain high standards for execution and interpretation Stay current with emerging technologies in CRISPR specificity, base editing, off-target discovery, targeted validation, genomic integrity assessment, and therapeutic genome editing Qualifications PhD (or equivalent) in molecular biology, genomics, genome editing, biochemistry, bioengineering, genetics, chemical biology, or a related field with 2-4 years of relevant industry experience in genome editing specificity and genomic safety assessment Deep expertise and hands-on experience with CRISPR-based genome editing systems, particula